Showing 4641-4650 of 9153 results for "".
- Welcome to Camp Dermhttps://practicaldermatology.com/news/welcome-to-camp-derm/2461816/As kids across the country got ready for summer camp, dermatologists flocked to Brooklyn, NY for their own version of summer camp: Neutrogena’s immersive SkinU Summer Camp. Instead of learning to swim, sliding down a zipline, or playing tennis like kids in camp ofte
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermat
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to
- Paradigm Shift: Can Harnessing the Power of Healthy Cells Prevent Skin Cancer?https://practicaldermatology.com/news/paradigm-switch-can-harnessing-the-power-of-healthy-cells-prevent-skin-cancer/2461803/Do simple wounds or surgery increase skin cancer risks by expanding mutated cells? No, according to a new study by researchers at Yale and the Karolinska Institute in Sweden. Rather than promoting mutant cell growth, injury promotes healthy-cell expansion which keeps mutated cell growth
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4
- Cedric Burg Named New COO at Innovadermhttps://practicaldermatology.com/news/cedric-burg-named-new-coo-at-innovaderm/2461798/Cedric Burg is Innovaderm’s new Chief Operating Officer. Mr. Burg’s new role entails the management of Innovaderm’s global operations in Canada, through the close collaboration between department heads while overseeing most of Innovaderm’s activi
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Deloitte Launches 'Illustrate Change' Medical Illustration Libraryhttps://practicaldermatology.com/news/deloitte-launches-illustrate-change-medical-illustration-library/2461794/Deloitte is launching "Illustrate Change," a project that seeks to increase representation in medical i
- Study: Minimal Systemic Absorption of Isotretinoin Seen in Congenital Ichthyosishttps://practicaldermatology.com/news/study-minimal-systemic-absorption-of-isotretinoin-seen-in-congenital-ichthyosis/2461793/Interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study suggest minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment, Timber Pharmaceuticals, Inc. repor